Deals, Partnering

Seattle Genetics and Agensys expand antibody-drug conjugate collaboration

Posted on 23 November 2009

Under the amended agreement, Agensys will pay a $12 million fee for exclusive rights to ADC licenses against additional antigen targets. Seattle Genetics also receives an option to co-develop another ADC at the time of investigational new drug (IND) submission.

Print Friendly, PDF & Email

Leave a Reply